Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma.

Autor: Merryman RW; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. Reid_merryman@dfci.harvard.edu., Castagna L; Department of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano-Milano, Italy., Giordano L; Department of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano-Milano, Italy., Ho VT; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Corradini P; Division of Hematology and Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy., Guidetti A; Division of Hematology and Bone Marrow Transplantation, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Milano, Milano, Italy., Casadei B; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università Degli Studi, Bologna, Italia., Bond DA; Division of Hematology, The Ohio State University, Columbus, OH, USA., Jaglowski S; Division of Hematology, The Ohio State University, Columbus, OH, USA., Spinner MA; Department of Medicine, Stanford University Medical Center, Stanford, CA, USA., Arai S; Department of Medicine, Stanford University Medical Center, Stanford, CA, USA., Lowsky R; Department of Medicine, Stanford University Medical Center, Stanford, CA, USA., Shah GL; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Perales MA; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA., De Colella JMS; Programme de Transplantation & Therapie Cellulaire, Centre de Recherche en Cancérologie de Marseille, Institut Paoli Calmettes, Marseille, France., Blaise D; Institut Paoli-Calmettes, Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France., Herrera AF; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA., Shouse G; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA, USA., Spilleboudt C; Service Hématologie, Institut Bordet, Bruxelles, Belgium., Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Nieto Y; Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA., Badar T; Division of Hematology and Oncology, Mayo Clinic, Jacksonville, FL, USA., Hamadani M; BMT & Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI, USA., Feldman TA; John Theurer Cancer Center at HMH, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA., Dahncke L; John Theurer Cancer Center at HMH, Hackensack Meridian Health School of Medicine, Hackensack, NJ, USA., Singh AK; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA., McGuirk JP; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA., Nishihori T; Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Chavez J; Department of Blood & Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL, USA., Serritella AV; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA., Kline J; Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL, USA., Mohty M; Service d'Hématologie Clinique et de Thérapie Cellulaire, Hospital Saint Antoine, Sorbonne University, Paris, France., Dulery R; Department of Hematology, Centre Henri Becquerel, Rouen, France., Stamatoulas A; Department of Hematology, Centre Henri Becquerel, Rouen, France., Houot R; Department of Hematology, CHU Rennes, University of Rennes, Inserm U1236, Rennes, France., Manson G; Department of Hematology, CHU Rennes, University of Rennes, Inserm U1236, Rennes, France., Moles-Moreau MP; CHU Angers, Angers, France., Orvain C; CHU Angers, Angers, France., Bouabdallah K; Hematology Clinic, University Hospital of Bordeaux, Pessac, France., Modi D; Department of Oncology, Karmanos Cancer Institute/Wayne State University, Detroit, MI, USA., Ramchandren R; Division of Hematology/Oncology, University of Tennessee School of Medicine, Knoxville, TN, USA., Lekakis L; Division of Transplantation and Cellular Therapy, University of Miami/Sylvester Cancer Center, Miami, FL, USA., Beitinjaneh A; Division of Transplantation and Cellular Therapy, University of Miami/Sylvester Cancer Center, Miami, FL, USA., Frigault MJ; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA., Chen YB; Blood and Marrow Transplant Program, Massachusetts General Hospital, Boston, MA, USA., Lynch RC; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Smith SD; University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Rao U; Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA., Byrne M; Department of Medicine, Division of Hematology-Oncology, Vanderbilt University Medical Center, Nashville, TN, USA., Romancik JT; Emory University Winship Cancer Institute, Atlanta, GA, USA., Cohen JB; Emory University Winship Cancer Institute, Atlanta, GA, USA., Nathan S; Section of Bone Marrow Transplant and Cell Therapy, Rush University Medical Center, Chicago, IL, USA., Phillips T; Division of Hematology and Oncology, University of Michigan, Ann Arbor, MI, USA., Joyce RM; Division of Hematologic Malignancy, Beth Israel Deaconess Medical Center, Boston, MA, USA., Rahimian M; Division of Hematologic Malignancy, Beth Israel Deaconess Medical Center, Boston, MA, USA., Bashey A; Blood and Marrow Transplant Program at Northside Hospital, Atlanta, GA, USA., Ballard HJ; Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Svoboda J; Division of Hematology-Oncology, Department of Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, USA., Torri V; Laboratory of Methodology of Clinical Research, Oncology Department. IRCCS Mario Negri Institute, Milano, Italy., Sollini M; Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia., De Philippis C; Department of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano-Milano, Italy., Magagnoli M; Department of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano-Milano, Italy., Santoro A; Department of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano-Milano, Italy., Armand P; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Zinzani PL; Istituto di Ematologia 'Seràgnoli', Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale Università Degli Studi, Bologna, Italia.; Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italia., Carlo-Stella C; Department of Oncology and Hematology, Humanitas Clinical and Research Center-IRCCS, Rozzano-Milano, Italy.; Department of Biomedical Sciences, Humanitas University, Rozzano-Milan, Italy.
Jazyk: angličtina
Zdroj: Leukemia [Leukemia] 2021 Sep; Vol. 35 (9), pp. 2672-2683. Date of Electronic Publication: 2021 Mar 03.
DOI: 10.1038/s41375-021-01193-6
Abstrakt: Anti-PD-1 monoclonal antibodies yield high response rates in patients with relapsed/refractory classic Hodgkin lymphoma (cHL), but most patients will eventually progress. Allogeneic hematopoietic cell transplantation (alloHCT) after PD-1 blockade may be associated with increased toxicity, raising challenging questions about the role, timing, and optimal method of transplantation in this setting. To address these questions, we assembled a retrospective cohort of 209 cHL patients who underwent alloHCT after PD-1 blockade. With a median follow-up among survivors of 24 months, the 2-year cumulative incidences (CIs) of non-relapse mortality and relapse were 14 and 18%, respectively; the 2-year graft-versus-host disease (GVHD) and relapse-free survival (GRFS), progression-free survival (PFS), and overall survival were 47%, 69%, and 82%, respectively. The 180-day CI of grade 3-4 acute GVHD was 15%, while the 2-year CI of chronic GVHD was 34%. In multivariable analyses, a longer interval from PD-1 to alloHCT was associated with less frequent severe acute GVHD, while additional treatment between PD-1 and alloHCT was associated with a higher risk of relapse. Notably, post-transplant cyclophosphamide (PTCy)-based GVHD prophylaxis was associated with significant improvements in PFS and GRFS. While awaiting prospective clinical trials, PTCy-based GVHD prophylaxis may be considered the optimal transplantation strategy for this patient population.
(© 2021. The Author(s), under exclusive licence to Springer Nature Limited part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: